RRP9 and acute myeloid leukemia: Based on our findings that chidamide combined with cytarabine inhibits the MYC-RRP9 pathway (Figs. 3 and 4) and that reduced RRP9 impairs ribosome biogenesis in AML (Fig. 6), we further examined the effects of this combination on ribosome biogenesis.